Abstract:Background Oncolytic viruses are considered part of immunotherapy and have shown promise in preclinical experiments and clinical trials. Results from these studies have suggested that tumor microenvironment remodeling is required to achieve an effective response in solid tumors. Here, we assess the extent to which targeting specific mechanisms underlying the immunosuppressive tumor microenvironment optimizes viroimmunotherapy. Methods We used RNA-seq analyses to analyze the transcriptome, and validated the results using Q-PCR, flow cytometry, and immunofluorescence. Viral activity was analyzed by replication assays and viral titration. Kyn and Trp metabolite levels were quantified using liquid chromatography–mass spectrometry. Aryl hydrocarbon receptor (AhR) activation was analyzed by examination of promoter activity. Therapeutic efficacy was assessed by tumor histopathology and survival in syngeneic murine models of gliomas, including Indoleamine 2,3-dioxygenase (IDO)-/- mice. Flow cytometry was used for immunophenotyping and quantification of cell populations. Immune activation was examined in co-cultures of immune and cancer cells. T-cell depletion was used to identify the role played by specific cell populations. Rechallenge experiments were performed to identify the development of anti-tumor memory. Results Bulk RNA-seq analyses showed the activation of the immunosuppressive IDO-kynurenine-AhR circuitry in response to Delta-24-RGDOX infection of tumors. To overcome the effect of this pivotal pathway, we combined Delta-24-RGDOX with clinically relevant IDO inhibitors. The combination therapy increased the frequency of CD8 + T cells and decreased the rate of myeloid-derived suppressor cell and immunosupressive Treg tumor populations in animal models of solid tumors. Functional studies demonstrated that IDO-blockade-dependent activation of immune cells against tumor antigens could be reversed by the oncometabolite kynurenine. The concurrent targeting of the effectors and suppressors of the tumor immune landscape significantly prolonged the survival in animal models of orthotopic gliomas. Conclusions Our data identified for the first time the in vivo role of IDO-dependent immunosuppressive pathways in the resistance of solid tumors to oncolytic adenoviruses. Specifically, the IDO-Kyn-AhR activity was responsible for the resurface of local immunosuppression and resistance to therapy, which was ablated through IDO inhibition. Our data indicate that combined molecular and immune therapy may improve outcomes in human gliomas and other cancers treated with virotherapy.

Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening

Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity

Efficacy and Safety of Oncolytic Virus Immunotherapy in Advanced Malignancies: A Systematic Review of 161 Clinical Studies

Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

Oncolytic virus therapy for malignant gliomas: entering the new era

Longitudinal analysis of glioblastoma response to oncolytic HSV1 guides PLX3397 combination for enhanced viral permissiveness

Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity

Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy

The investigation of oncolytic viruses in the field of cancer therapy

Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry

A viral attack on brain tumors: the potential of oncolytic virus therapy

Immu-11. Guardians Of Innate Immune Activation: Crucial Roles Of Nono And Cgamp In Glioma Virotherapy

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas

An Oncolytic HSV-1 Armed with Visfatin Enhances Antitumor Effects by Remodeling Tumor Microenvironment Against Murine Pancreatic Cancer

Abstract LB262: Reprogramming the tumor microenvironment by targeting IGF2-IGF1R signaling, enhancing viro-immunotherapy

Simultaneous Expression of Different Therapeutic Genes by Infection with Multiple Oncolytic HSV-1 Vectors

Genetic Modifications That Expand Oncolytic Virus Potency

Gospel of malignant Glioma: Oncolytic virus therapy

CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma

The emerging field of oncolytic virus-based cancer immunotherapy